drugset / Trial / NCT00409994

Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer

NCT00409994

NaSingle-groupOpen-labelTreatment

Summary

Investigating the safety and the activity of Rapamycin, administered before and during preoperative radiotherapy in patients with an operable colorectal carcinoma. The phase I dose escalation study will be performed in three steps (2, 4 and 6 mg). Patients entered in phase II will follow the same tolerable treatment regimen as patients in phase I study.

Timeline

Start
2006-09
Primary completion
2018-08-03
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 2 mg Oral
Subject Sirolimus Small molecule 4 mg Oral
Subject Sirolimus Small molecule 6 mg Oral

Indications